Sensorion SA (EPA: ALSEN)

France flag France · Delayed Price · Currency is EUR
0.680
+0.006 (0.89%)
Aug 30, 2024, 5:36 PM CET
Market Cap 204.22M
Revenue 5.57M
Net Income -22.06M
Shares Out 300.33M
EPS -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,933
Open 0.674
Previous Close 0.674
Day's Range 0.674 - 0.684
52-Week Range 0.403 - 1.040
Beta 1.31
Analysts n/a
Price Target n/a
Earnings Date Sep 18, 2024

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 cli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 57
Stock Exchange Euronext Paris
Ticker Symbol ALSEN
Full Company Profile

News

There is no news available yet.